Genertec Universal Medical Group
Market Cap
HK$10.3b
Last Updated
2021/01/21 17:25 UTC
Data Sources
Company Financials +
Executive Summary
Genertec Universal Medical Group Company Limited provides financing and advisory services in the People’s Republic of China. More Details
Rewards
Risk Analysis
Snowflake Analysis
Very undervalued with acceptable track record.
Similar Companies
Share Price & News
How has Genertec Universal Medical Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2666 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 2666's weekly volatility (3%) has been stable over the past year.
Market Performance
7 Day Return
1.7%
2666
7.9%
HK Healthcare
5.7%
HK Market
1 Year Return
7.0%
2666
-11.4%
HK Healthcare
14.3%
HK Market
Return vs Industry: 2666 exceeded the Hong Kong Healthcare industry which returned -11.4% over the past year.
Return vs Market: 2666 underperformed the Hong Kong Market which returned 14.3% over the past year.
Shareholder returns
| 2666 | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.7% | 7.9% | 5.7% |
| 30 Day | 2.2% | 7.6% | 13.6% |
| 90 Day | 11.3% | 23.1% | 19.6% |
| 1 Year | 13.6%7.0% | -9.1%-11.4% | 18.9%14.3% |
| 3 Year | n/a | -40.8%-44.6% | -2.9%-13.1% |
| 5 Year | n/a | -20.5%-28.4% | 70.9%42.2% |
Long-Term Price Volatility Vs. Market
How volatile is Genertec Universal Medical Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Genertec Universal Medical Group undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 2666 (HK$5.99) is trading below our estimate of fair value (HK$12.52)
Significantly Below Fair Value: 2666 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 2666 is good value based on its PE Ratio (5.8x) compared to the HK Healthcare industry average (21.6x).
PE vs Market: 2666 is good value based on its PE Ratio (5.8x) compared to the Hong Kong market (11.9x).
Price to Earnings Growth Ratio
PEG Ratio: 2666 is good value based on its PEG Ratio (0.6x)
Price to Book Ratio
PB vs Industry: 2666 is good value based on its PB Ratio (0.7x) compared to the HK Healthcare industry average (1.5x).
Next Steps
Future Growth
How is Genertec Universal Medical Group forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
9.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2666's forecast earnings growth (9.8% per year) is above the savings rate (1.5%).
Earnings vs Market: 2666's earnings (9.8% per year) are forecast to grow slower than the Hong Kong market (21.3% per year).
High Growth Earnings: 2666's earnings are forecast to grow, but not significantly.
Revenue vs Market: 2666's revenue (15.6% per year) is forecast to grow faster than the Hong Kong market (14.2% per year).
High Growth Revenue: 2666's revenue (15.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2666's Return on Equity is forecast to be low in 3 years time (16.3%).
Next Steps
Past Performance
How has Genertec Universal Medical Group performed over the past 5 years?
18.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2666 has high quality earnings.
Growing Profit Margin: 2666's current net profit margins (19.3%) are lower than last year (26.5%).
Past Earnings Growth Analysis
Earnings Trend: 2666's earnings have grown by 18.4% per year over the past 5 years.
Accelerating Growth: 2666's earnings growth over the past year (2.9%) is below its 5-year average (18.4% per year).
Earnings vs Industry: 2666 earnings growth over the past year (2.9%) exceeded the Healthcare industry -9.1%.
Return on Equity
High ROE: 2666's Return on Equity (11.6%) is considered low.
Next Steps
Financial Health
How is Genertec Universal Medical Group's financial position?
Financial Position Analysis
Short Term Liabilities: 2666's short term assets (CN¥55.2B) exceed its short term liabilities (CN¥18.2B).
Long Term Liabilities: 2666's short term assets (CN¥55.2B) exceed its long term liabilities (CN¥27.0B).
Debt to Equity History and Analysis
Debt Level: 2666's debt to equity ratio (263.5%) is considered high.
Reducing Debt: 2666's debt to equity ratio has reduced from 460.3% to 263.5% over the past 5 years.
Debt Coverage: 2666's debt is not well covered by operating cash flow (9.2%).
Interest Coverage: Insufficient data to determine if 2666's interest payments on its debt are well covered by EBIT.
Balance Sheet
Next Steps
Dividend
What is Genertec Universal Medical Group current dividend yield, its reliability and sustainability?
4.83%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 2666's dividend (4.83%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.04%).
High Dividend: 2666's dividend (4.83%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.52%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 2666 has been paying a dividend for less than 10 years.
Growing Dividend: 2666's dividend payments have increased, but the company has only paid a dividend for 5 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (30.3%), 2666's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 2666's dividends in 3 years are forecast to be well covered by earnings (32.8% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.2yrs
Average management tenure
CEO
Jiahong Peng (49 yo)
2.17yrs
Tenure
CN¥4,420,000
Compensation
Ms. Jiahong Peng has been Vice-Chairwoman and Chief Executive Officer of Genertec Universal Medical Group Company Ltd since November 30, 2018 and serves as its General Manager. Ms. Peng served as the Chief...
CEO Compensation Analysis
Compensation vs Market: Jiahong's total compensation ($USD683.63K) is about average for companies of similar size in the Hong Kong market ($USD576.47K).
Compensation vs Earnings: Jiahong's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice-Chairwoman | 2.17yrs | CN¥4.42m | 0.44% CN¥ 45.6m | |
| Executive Director | 2.17yrs | CN¥4.14m | no data | |
| Deputy General Manager | 6yrs | no data | no data | |
| Deputy General Manager | 3.92yrs | no data | no data | |
| Deputy General Manager | 1.92yrs | no data | no data | |
| Company Secretary | 1.08yrs | no data | no data |
2.2yrs
Average Tenure
49yo
Average Age
Experienced Management: 2666's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice-Chairwoman | 2.17yrs | CN¥4.42m | 0.44% CN¥ 45.6m | |
| Executive Director | 2.17yrs | CN¥4.14m | no data | |
| Non-Executive Chairman | no data | no data | no data | |
| Independent Non-Executive Director | 5.58yrs | CN¥187.00k | no data | |
| Non-Executive Director | 8.58yrs | CN¥187.00k | no data | |
| Non-Executive Director | 8.75yrs | CN¥126.00k | 0.012% CN¥ 1.2m | |
| Independent Non-Executive Director | 5.58yrs | CN¥187.00k | no data | |
| Non-Executive Director | 6.08yrs | CN¥187.00k | no data | |
| Independent Non-Executive Director | 4.75yrs | CN¥187.00k | no data | |
| Non-Executive Director | 2.17yrs | no data | no data | |
| Independent Non-Executive Director | 1.08yrs | no data | no data |
5.2yrs
Average Tenure
57yo
Average Age
Experienced Board: 2666's board of directors are considered experienced (5.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Genertec Universal Medical Group Company Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Genertec Universal Medical Group Company Limited
- Ticker: 2666
- Exchange: SHSC
- Founded: 1984
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: HK$10.281b
- Shares outstanding: 1.72b
- Website: https://www.universalmsm.com
Number of Employees
Location
- Genertec Universal Medical Group Company Limited
- Hademen Plaza
- 4th, 5th and 13th Floor
- Beijing
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 2666 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Domestic Shares | HK | HKD | Jul 2015 |
| 5UM | DB (Deutsche Boerse AG) | Yes | Domestic Shares | DE | EUR | Jul 2015 |
| 2666 | SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect) | Yes | Domestic Shares | HK | HKD | Jul 2015 |
| UMTA.F | OTCPK (Pink Sheets LLC) | Yes | Domestic Shares | US | USD | Jul 2015 |
| 2666 | SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect) | Yes | Domestic Shares | HK | HKD | Jul 2015 |
Biography
Genertec Universal Medical Group Company Limited provides financing and advisory services in the People’s Republic of China. The company operates in two segments, Finance and Advisory and Hospital Group. T...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/21 17:25 |
| End of Day Share Price | 2021/01/21 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.